연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
3825. Phenotype of pheochromocytoma and paraganglioma by germline mutation: a Korean multicenter study
Min Jeong Park, Seung Shin Park, Bon Hyang Lee, Jin Sun Jang, Won Woong Kim, Su Jin Kim, Yu-Mi Lee, Kyu Eun Lee, Tae-Yon Sung, Moon-Woo Seong, Woochang Lee, Jung-Min Koh, Jung Hee Kim, and Seung Hun Lee
Endocr Relat Cancer. 2025 Mar 20;32(5):e240269
Link
3824. Proliferation of tumor-related regulatory T cells in circulation dictates efficacy of chemoimmunotherapy in triple-negative breast cancer
Jeon SH, Suh KJ, Jung S, Jeon M, Jang HC, Kim ES, Kim SH, Lee KH, Im SA, Kim MH, Sohn J, Jeong JH, Jung KH, Lee KE, Park YH, Kim HJ, Cho EK, Choi IS, Park SY, Kim M, Kim JH, Shin EC
Clinical cancer research 31(21):4586-4597.
Link
3823. Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)
Lee J, Ahn HK, Lee KH, Jung KH, Park YH, Sim SH, Kim MH, Kim JH, Kim JH, Lee KE, Park KH, Bae J, Lee MH, Lim S, Kim HJ, Lee DW, Jeong JH, Kim JY, Ahn JS, Lee KS, Sohn J, Suh KJ, Cha YJ, Shin K, Kim SB, Chae H, Kim GM, Im SA, Park IH
BMC cancer 25(1):1295.
Link
3822. Safety and Effectiveness of Eribulin in Patients with Advanced or Metastatic Breast Cancer Previously Treated with Anthracyclines and Taxanes in Real-World Clinical Practice: A 6-Year Post-Marketing Surveillance Study in South Korea
Chae YS, Kwon KA, Lee MH, Ahn MS, Lee KH, Koh SJ, Sohn J, Park KU, Kim MY, Pyo Y, Kim BY, Jung KH.
Cancer Res Treat. 2025 Apr 28. doi: 10.4143/crt.2024.1142. Online ahead of print.
Link
3821. Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 study
Ahn HK, Kim JY, Lee KH, Kim GM, Kang SY, Lee KS, Kim JH, Lee KE, Lee MH, Kim HJ, Kim HJ, Koh SJ, Park IH, Sohn J, Kim SB, Ahn JS, Kim S, Cho H, Jung KH, Im SA, Park YH
The Lancet. Oncology 26(3):343-354.
Link
3820. Bench-Stable Copper Complex for Trifluoromethylation and 18F-Labeling of Aryl Iodides.
Choi JY, Pietrasiak E, Ko N, Lee SY, Youn H, Kim J, Lee E, Lee BC.
Org Lett. 2025 Sep 12;27(36):10110-10115.
Link
3819. First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial.
Lowery MA, Wyrwicz LS, Oh DY, Shiu KK, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Fernández MG, Li J, Çil T, Cruz FM, Qin S, Guan Y, Valderrama A, Bordia S, Rha SY.
Eur J Cancer. 2025 Dec 9:231:115807.
Link
3818. Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial.
Janjigian YY, Oh DY, Pelster M, Wainberg ZA, Prusty S, Nelson S, DuPage A, Thompson A, Koralek DO, Sison EAR, Rha SY.
Nat Med. 2025 Dec;31(12):4274-4280.
Link
3817. Final Results from a First-in-Human Phase 1 Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.
Harding JJ, Oh DY, Mercade TM, Goyal L, Varkaris A, Palmieri LJ, Ikeda M, Kondo S, Bai LY, Ueno M, Chen LT, Papadopoulos KP, Shroff RT, Kizilbash SH, Hollebecque A, Adeva J, Cosman R, Yokota T, Park JO, Turk A, Liao CY, Satoh T, Borad MJ, El-Khoueiry A, Azad N, Jaeckle KA, Loong HH, Yong WP, Bender MH, Varughese SC, Sachdeva D, Radtke DB, Gueorguieva I, Szpurka AM, Chen HR, Liu H, Xu X, Rodon J.
Clin Cancer Res. 2025 Dec 1;31(23):4920-4932.
Link
3816. A phase III randomised study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer.
Knox JJ, McNamara MG, Bazin IS, Oh DY, Zubkov O, Breder V, Bai LY, Christie A, Goyal L, Cosgrove DP, Springfeld C, Sjoquist KM, Oh Park J, Verdaguer H, Braconi C, Ross PJ, De Gramont A, Shroff RT, Zalcberg JR, Palmer DH, Smith JR, Oelmann E, Bruce T, Valle JW.
J Hepatol. 2025 Aug;83(2):358-366.
Link